{
  "context": {
    "rules": [
      "Rule1: Provided that patient1 adheres to the protocol, if the treatment in trial1 is not effective, then patient1 shows abstinence.",
      "Rule2: If researcher1 is blinded as an investigator, then whenever patient1 attends the study visits, patient1 adheres to the protocol.",
      "Rule3: Either researcher1 is blinded as an investigator or nurse1 is blinded as a coordinator.",
      "Rule4: If nurse1 is blinded as a coordinator, then given that patient1 attends the study visits, patient1 adheres to the protocol.",
      "Rule5: A protocol violation occurs in trial1, or the data for trial1 is audited, or the treatment in trial1 is effective.",
      "Rule6: Provided that monitor1 conducts monitoring for trial1, a protocol violation does not occur in trial1.",
      "Rule7: Monitor1 conducts monitoring for trial1, or statistician1 performs an interim analysis for trial1.",
      "Rule8: If the ethics board (IRB) approves trial1, then the agency (FDA) approves trial1.",
      "Rule9: If the ethics board (IRB) approves trial1, then committee1 (DSMB) reviews trial1.",
      "Rule10: If the agency (FDA) approves trial1, then provided that it is not the case that 'if an interim analysis is performed, then a protocol violation does not occur', trial1 is not halted.",
      "Rule11: If craving is reduced for patient1, then the treatment in trial1 is effective.",
      "Rule12: Provided that consumption is decreased for patient1, the treatment in trial1 is effective.",
      "Rule13: If patient1 receives an intervention, then craving is reduced for patient1.",
      "Rule14: Under the condition that patient1 gets support, consumption is decreased for patient1.",
      "Rule15: If patient1 meets the secondary endpoint, then patient1 receives an intervention or gets support.",
      "Rule16: If a paper for trial1 is published in journal1, then given that statistical significance is reached, if patient1 meets the primary endpoint, patient1 meets the secondary endpoint.",
      "Rule17: A paper for trial1 is published in journal1, or the results of trial1 are presented at conference1.",
      "Rule18: If the results of trial1 are presented at conference1, then under the condition that statistical significance is reached, if patient1 meets the primary endpoint, patient1 meets the secondary endpoint.",
      "Rule19: Provided that a biological sample (blood) is collected from patient1, the treatment in trial1 is effective.",
      "Rule20: Whenever the European agency (EMA) reviews trial1, then if it is not the case that 'if patient1 has a poor metabolizer status, then a pharmacogenetic response occurs', the dose for patient1 is adjusted.",
      "Rule21: If patient1 uses a diary, then if the treatment in trial1 is not effective, patient1 shows abstinence.",
      "Rule22: Patient1 uses a diary, or patient1 wears a sensor.",
      "Rule23: If patient1 receives a placebo, then whenever patient1 reports a headache as an adverse event, patient1 does not experience nausea as a side effect.",
      "Rule24: If patient1 completes the AUDIT-C questionnaire, then data is not missing for patient1.",
      "Rule25: Under the condition that clinician1 conducts an interview with patient1, data is not missing for patient1.",
      "Rule26: Grant1 funding is continued, or patient1 completes the AUDIT-C questionnaire, or clinician1 conducts an interview with patient1.",
      "Rule27: If the protocol for trial1 is amended to version2, then given that committee1 (DSMB) reviews trial1, if it is not the case that 'if an interim analysis is performed, then a protocol violation does not occur', trial1 is not halted.",
      "Rule28: Trial1 undergoes a multicenter expansion, or if the protocol for trial1 is not amended to version2, then recruitment for trial1 is paused.",
      "Rule29: Patient1 completes the 6-month follow-up, or long-term data is collected from patient1 at year1.",
      "Rule30: If long-term data is collected from patient1 at year1, then whenever patient1 meets the primary endpoint, patient1 receives an intervention or gets support.",
      "Rule31: Replication study trial2 is initiated, or if patient1 completes the 6-month follow-up, then given that patient1 meets the primary endpoint, patient1 receives an intervention or gets support.",
      "Rule32: Patient1 has a contraindication (a liver condition), or if patient1 is randomized into groupA, then patient1 receives a placebo.",
      "Rule33: If patient1 takes the study drug, naltrexone, then patient1 attends the study visits.",
      "Rule34: Patient1 takes the study drug, naltrexone, or patient1 receives counseling.",
      "Rule35: Under the condition that patient1 receives counseling, if the treatment in trial1 is not effective, then patient1 shows abstinence.",
      "Rule36: If it is not the case that 'if patient1 completes trial1, then the treatment is effective', then patient1 experiences nausea as a side effect.",
      "Rule37: Provided that it is not the case that 'if patient1 completes trial1, then the treatment is effective', patient1 reports a headache as an adverse event.",
      "Rule38: Whenever it is not the case that 'if an interim analysis is performed, then a protocol violation does not occur', trial1 is halted.",
      "Rule39: Under the condition that it is not the case that 'if patient1 wears a sensor, then if the treatment is not effective, patient1 shows abstinence', data is missing for patient1.",
      "Rule40: Provided that it is not the case that 'if it is not the case that 'if a biological sample is not collected from patient1, then a biomarker is analyzed', then a genetic variant is found in patient1', patient1 has a poor metabolizer status.",
      "Rule41: If it is not the case that 'if it is not the case that 'if a biological sample is not collected from patient1, then a biomarker is analyzed', then a genetic variant is found in patient1', then a pharmacogenetic response does not occur in patient1.",
      "Rule42: Provided that a biological sample is not collected from patient1, lab1 does not analyze biomarker sample1.",
      "Rule43: Under the condition that the protocol for trial1 is not amended to version2, recruitment for trial1 is not paused.",
      "Rule44: Provided that the treatment in trial1 is not effective, patient1 does not show abstinence."
    ],
    "facts": [
      "Fact1: Patient1 completes trial1.",
      "Fact2: The ethics board (IRB) approves trial1.",
      "Fact3: Patient1 meets the primary endpoint.",
      "Fact4: Statistical significance for outcome1 is reached in trial1.",
      "Fact5: The European agency (EMA) reviews trial1.",
      "Fact6: Patient1 is randomized into groupA.",
      "Fact7: It is not the case that the data for trial1 is audited.",
      "Fact8: A genetic variant (allele1) is not found in patient1.",
      "Fact9: The dose for patient1 is not adjusted.",
      "Fact10: Grant1 funding is not continued.",
      "Fact11: Trial1 does not undergo a multicenter expansion.",
      "Fact12: Replication study trial2 is not initiated.",
      "Fact13: Patient1 does not have a contraindication: a liver condition."
    ]
  },
  "question": "The treatment in trial1 is effective."
}